Hypofractionated stereotactic boost in intermediate risk prostate carcinoma

Dose escalation may improve curability in intermediate-risk prostate carcinoma. A multi-centre national program was developed to assess toxicity and tumour response with hypofractionated stereotactic boost after conventional radiotherapy in intermediate-risk prostate cancer.
UroToday